ESC TV Today – Your Cardiovascular News

Host: Emer Joyce Guest: Steffen Massberg Want to watch that extended interview on https://esc365.escardio.org/event/2178?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests Emer Joyce and Steffen Massberg have declared to have no potential conflicts of interest to report.

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Steffen Massberg Want to watch that extended interview on https://esc365.escardio.org/event/2178?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests Emer Joyce and Steffen Massberg have declared to have no potential conflicts of interest to report.

Folkert Asselbergs, Professor of Cardiology and digital health expert, dives into the transformative role of large language models in clinical settings. He discusses how these models can automate administrative tasks and even serve as AI companions grounded in ESC guidelines. Folkert addresses concerns about hallucinations and bias, and argues for innovative evaluation methods over traditional trials. He encourages democratized patient access to AI tools while emphasizing data security and the potential for personal health apps in the future.

Folkert Asselbergs, a cardiologist and expert in digital health and AI, discusses the implications of large language models (LLMs) in clinical settings, including their role in patient engagement and reducing clinician workload. Massimo Imazio, chair of the upcoming ESC guidelines on myocarditis, delves into the nuances of diagnosing myocarditis, emphasizing cardiac MRI and biopsies when necessary. He also provides critical insights on managing immune-related myocarditis and guidelines for returning patients to physical activity.

In this insightful discussion, Erik Stroes, an academic clinician from Amsterdam University Medical Center with expertise in lipid disorders, delves into the significance of Lp(a) in cardiovascular health. He highlights how elevated Lp(a) is prevalent yet often overlooked in risk assessments. Erik explains the limited impact of lifestyle changes and current medications on lowering Lp(a), and he emphasizes the need for routine testing to enhance risk prediction. He also shares insights on the clinical significance of Lp(a)-lowering therapies and their prioritization in high-risk patients.

Erik Stroes, a leading cardiologist from Amsterdam, dives into the intricate biology of Lp(a) and highlights emerging therapies set to transform cardiovascular care. Vijay Kunadian, an expert in treating older and frail patients, discusses nuanced management strategies for myocardial infarction. They debate the importance of screening for Lp(a) and weigh the benefits of invasive versus conservative approaches for older adults. JP Carpenter contributes a witty 'Mythbusters' segment, debunking common beliefs about beetroot’s impact on heart health.

In this engaging discussion, cardiology specialist Stephanie Schwarting, affiliated with renowned institutions in Munich and Heidelberg, shares her expertise on arrhythmias within cardiac amyloidosis. She delves into the complexities of rate control influenced by heart rate dependence and autonomic dysfunction. The conversation covers the challenges of ablation based on disease stage and the unpredictable progression of conduction disease. Schwarting also emphasizes the importance of individualized monitoring strategies and the role of multidisciplinary teams in enhancing patient care.

Stephanie Schwarting, a cardiac amyloidosis expert from University Hospital Munich, dives into arrhythmias in transthyretin cardiac amyloidosis, discussing management strategies and the nuances of treating atrial fibrillation in this context. Ahmad Masri, a cardiologist specializing in hypertrophic cardiomyopathy from Oregon Health & Science University, explores the complexities of managing LVOT obstruction and the role of myosin inhibitors versus traditional therapies. Both guests provide invaluable insights into cutting-edge treatments and patient management approaches.

Join cardiologist Milton Packer as he dives into the critical role of visceral adiposity in managing heart failure with preserved ejection fraction (HFpEF). He explores how SGLT2 inhibitors and GLP-1 agonists shift adipose biology towards a protective state, challenging traditional views. The integration of artificial intelligence in echocardiography systems is also discussed, highlighting its potential for early disease detection and the importance of training on diverse populations to avoid bias. Packer's insights signal a pivotal shift in cardiovascular treatment strategies.